ASCO 2019: Active surveillance in metastatic kidney cancer

This study used data from the Canadian Kidney Cancer Information System and was presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago earlier this week. During the study, patient outcomes and safety data were collected from patients who underwent active surveillance and compared to those who received immediate systemic treatment. […]

read more

ASCO GU 2019: Questions and lessons moving forward from CARMENA: A medical oncologist’s perspective

The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Cytoreductive nephrectomy (CN) is defined as the surgical removal of the primary renal cell carcinoma (RCC) tumour before starting systemic therapy. The following paper from medical oncologist Dr Lauren Harshman, Dana-Farber Cancer Institute, Boston, USA, suggests that this is an […]

read more
Showing all 3 results
  TOP